Koers Aurinia Pharmaceuticals Inc. Toronto S.E.
Aandelen
CA05156V1022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 227 mln. 0 208 mln. | Omzet 2025 * | 282 mln. 0 259 mln. | Marktkapitalisatie | 827 mln. 0 759 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 9 mln. - 8,26 mln. | Nettowinst (verlies) 2025 * | 71 mln. - 65,13 mln. | EV/omzet 2024 * | 1,9 x |
Nettoliquiditeiten 2024 * | 395 mln. 0 363 mln. | Nettoliquiditeiten 2025 * | 448 mln. 0 411 mln. | EV/omzet 2025 * | 1,34 x |
K/w-verhouding 2024 * |
100
x | K/w-verhouding 2025 * |
12,3
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,93% |
Recentste transcriptie over Aurinia Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16-06-93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Robert Foster
FOU | Founder | 65 | 16-06-93 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16-06-93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26-06-19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 127 mld. | |
+24,67% | 117 mld. | |
+25,44% | 27,67 mld. | |
-17,74% | 20,33 mld. | |
-15,17% | 16,79 mld. | |
-15,21% | 15,63 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,65 mld. | |
+54,50% | 14,43 mld. |